Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases.

A programmatic latent tuberculosis infection (LTBI) intervention led to completion rates of 92.7% for LTBI screening and 82.5% for TB preventive therapy (TPT) among elderly patients with poorly controlled diabetes, according to study findings published in Clinical Infectious Diseases.

Multidrug-resistant tuberculosis (MDR-TB) was declared a public health crisis by the World Health Organization (WHO) in 2013 and each year continues to pose a serious threat to millions, especially to those infected with HIV. TB is one of the top 10 causes of death worldwide, and 15% of HIV-associated tuberculosis (TB) deaths were caused by MDR-TB in 2018. Furthermore, HIV patients are 20 times more likely to develop active TB than those without HIV.